<scp>JAK1</scp>/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid‐derived suppressor cells via the <scp>JAK</scp>/<scp>STAT</scp> and <scp>ROS‐MAPK</scp>/<scp>NF‐κB</scp> signalling pathways in acute graft‐versus‐host disease

Abstract

Ruxolitinib enhances PMN-MDSCs functions through JAK/STAT and ROS-MAPK/NF-κB signalling pathways. Monitoring frequencies and functions of MDSCs can help evaluate treatment responses to ruxolitinib.